Global Leading Market Research Publisher QYResearch announces the release of its latest report “Aeromonas Aminopeptidase – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Aeromonas Aminopeptidase market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Aeromonas Aminopeptidase was estimated to be worth US22millionin2025andisprojectedtoreachUS22millionin2025andisprojectedtoreachUS34 million by 2032, growing at a CAGR of 6.5% from 2026 to 2032. For protein biochemists, mass spectrometry specialists, and industrial biotechnology researchers, the core business imperative lies in utilizing Aeromonas aminopeptidase that addresses the critical need for a broad-specificity, heavy-metal-tolerant, heat-stable exopeptidase that selectively removes N-terminal amino acids from peptides and proteins for applications including protein sequencing (Edman degradation alternative), mass spectrometry-based peptide fingerprinting, protein truncation studies, N-terminal modification analysis, and removal of affinity tags. Aeromonas aminopeptidase is a zinc-metalloprotease (aminopeptidase) isolated from Aeromonas proteolytica (formerly Aeromonas aminopeptidase), with broad substrate specificity (cleaves leucine, alanine, methionine, phenylalanine, tyrosine, tryptophan, arginine, lysine from N-terminus). It is highly active at alkaline pH (7.5-9.0), stable at elevated temperatures (50-65°C), and retains activity in the presence of chaotropic agents (urea, guanidine HCl) and detergents (SDS (sodium dodecyl sulfate)), making it suitable for protein sequencing under denaturing conditions where other aminopeptidases fail. Applications: scientific research (protein sequencing, mass spectrometry (MALDI-TOF, ESI-MS (electrospray ionization mass spectrometry)), peptide mapping, N-terminal processing studies, enzyme kinetics, inhibitor screening), medical (biomarker discovery, diagnostic assay development), and others (biopharmaceutical characterization, quality control). Product purity grades: >95% (high purity, for MS, crystallography, kinetic studies) and <95% (research grade, for routine assays). Suppliers include Abbexa, Prospec TechnoGene, Merck, Medline, Takara Bio, R&D Systems, Thermo Fisher Scientific.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5985655/aeromonas-aminopeptidase
The Aeromonas Aminopeptidase market is segmented as below:
Abbexa
Prospec TechnoGene
Merck
Medline
Takara Bio
RND Systems
Thermo Fisher Scientific
Segment by Type
Purity Greater than 95%
Purity Less than 95%
Segment by Application
Scientific Research
Medical
Others
1. Market Drivers: Proteomics, Mass Spectrometry, and Biopharmaceutical QC
Several powerful forces are driving the Aeromonas aminopeptidase market:
Protein sequencing and mass spectrometry – Proteomics workflows (identification, characterization) require N-terminal truncation, ladder sequencing. Aeromonas aminopeptidase stable under denaturing conditions (4M urea, 0.1% SDS) (compatible with MS sample prep).
Biopharmaceutical characterization – Monoclonal antibodies (mAbs), recombinant proteins require N-terminal sequence confirmation, truncation analysis, and pyroglutamate removal (other aminopeptidases). QC lot release.
Tag removal and protein engineering – His-tag, FLAG-tag removal from recombinant proteins (N-terminal affinity tags). Aeromonas aminopeptidase cleaves linkage.
Recent market data (December 2025): According to Global Info Research analysis, high purity Aeromonas aminopeptidase (>95%) dominates with approximately 75% revenue share (MS-grade, structural biology). Research grade (<95%) 25% share. Scientific research (academic, biotech, pharma) largest application (80% share). Medical (biomarker discovery) 15% share. Others (bioprocessing, QC) 5% share. North America largest market (45% share). Europe 30% share. Asia-Pacific 20% share. Merck (Sigma), R&D Systems, Thermo Fisher Scientific (Pierce) leading suppliers.
2. Product Specifications
| Purity Grade | Purity (SDS-PAGE) | Specific Activity (U/mg) | Endotoxin Level | Application | Price (1 mg) | Share |
|---|---|---|---|---|---|---|
| High Purity (>95%) | >95-98% | >100-200 | <1.0 EU/mg | MS, crystallography, kinetics | US$200-500 | ~75% |
| Research Grade (<95%) | 85-95% | >50-100 | <10 EU/mg | Routine assay, tag removal | US$100-250 | ~25% |
Key specifications: Source (Aeromonas proteolytica, recombinant E. coli). Enzyme classification (EC 3.4.11.10, aminopeptidase). Molecular weight (29-32 kDa monomer, dimer active). Optimal pH (7.5-9.0). Optimal temperature (50-60°C). Substrate specificity (broad: Leu, Ala, Met, Phe, Tyr, Trp, Arg, Lys, less active on Pro, Gly, Glu). Inhibitors (bestatin, 1,10-phenanthroline, EDTA (metal chelator), not inhibited by PMSF (serine protease inhibitor)). Metal requirement (Zn²⁺, Co²⁺, Ca²⁺). pH stability (6.0-10.0). Storage (-20°C, 4°C short term). Buffer (Tris, NaCl, CaCl₂, ZnCl₂). Thermozyme: 50% activity retained after 1 hour at 65°C, stable in 4M urea, 0.1% SDS.
Exclusive observation (Global Info Research analysis): Aeromonas aminopeptidase is specialized tool for protein sequencing under denaturing conditions (unique). R&D Systems (Bio-Techne) and Merck (Sigma) main suppliers. Thermo Fisher (Pierce) offers as “Aminopeptidase M” (porcine, not Aeromonas). Activity measured using Leu-pNA (p-nitroanilide) substrate (1 unit = 1 µmol pNA released per minute at 25°C). Bacillus aminopeptidase not same.
User case – protein ladder sequencing (December 2025): Proteomics lab (US) identifies unknown protein (novel) from bacterial lysate. Partial Edman degradation fails (blocked N-terminus, pyroglutamate). Aeromonas aminopeptidase digestion (partial, time course) + MALDI-TOF MS (mass differences identify amino acids). Software de novo sequencing.
User case – biopharmaceutical N-terminal truncation (January 2026): QC lab (pharma) characterizes recombinant mAb (monoclonal antibody) batch (N-terminal heavy chain heterogeneity). Aeromonas aminopeptidase (R&D Systems) digest followed by LC-MS, quantify truncated species (<5% acceptance).
3. Technical Challenges
Metal ion requirement and inhibition – Zn²⁺/Co²⁺ required for activity. EDTA (ethylenediaminetetraacetic acid) chelation completely inhibits. Buffer optimization.
Broad specificity – Not specific for single amino acid; sequential hydrolysis (processive). MS ladder interpretation.
Technical difficulty – autolysis: Enzyme may self-digest (protease). Storage at -80°C, use freshly diluted.
Technical development (October 2025): Thermo Fisher Scientific (Pierce) introduced immobilized Aeromonas aminopeptidase resin (agarose beads). Enzymatic digestion, then removal (spin column) without protein contamination. MS compatible. Price US$300 per 0.5 mL resin.
4. Competitive Landscape
Key players include: Abbexa (UK), Prospec TechnoGene (Israel – recombinant), Merck (Germany – Sigma), Medline (US), Takara Bio (Japan), RND Systems (R&D Systems, Bio-Techne US), Thermo Fisher Scientific (US – Pierce). R&D Systems, Merck, Thermo Fisher leaders.
Regional dynamics: North America (R&D Systems, Merck, Thermo Fisher). Europe (Merck (Sigma Germany)). Asia-Pacific (Takara Bio Japan). Specialty niche market.
5. Outlook
Aeromonas aminopeptidase market will grow at 6.5% CAGR to US$34 million by 2032, driven by proteomics (MS), biopharmaceutical QC, and protein sequencing. Technology trends: immobilized enzyme (reusable), recombinant production (batch consistency), and heat-stable variants (thermoproteases). Asia-Pacific growth 7-8% CAGR. Niche but stable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
